Stem Cell Clinic

Asymmetrex’s Kinetic Stem Cell (KSC) Counting Technology Is Featured in the Parent’s Guide to Cord Blood Foundation June Newsletter – PR Web

The Parent's Guide to Cord Blood features Asymmetrex's technology for determining the dosage of therapeutic cord blood stem cells.

BOSTON (PRWEB) June 15, 2022

The Parent's Guide to Cord Blood Foundation is well known for its excellence in advocacy and education to support parents negotiating medical treatments for their children that involve umbilical cord blood and tissues. The Parent's Guide monthly newsletter has a goal of presenting new advances in umbilical cord medical research and treatments in terms that are accessible by parents and others who are not experts. The June 2022 issue, published June 14, provides a graphical presentation of stem cell biotechnology company Asymmetrex's technology that provides the dose of therapeutic umbilical cord stem cells for the first time.

Determining the dosage of therapeutic tissue stem cells is a long-standing unmet need for all tissue stem cell therapies. More commonly mis-called adult stem cells, tissue stem cells include stem cells found in adults, children, and birth tissues like the placenta and the umbilical cord. Donor umbilical cords are currently a major focus for sourcing therapeutic tissue stem cells, which are found in both their blood (hematopoietic stem cells) and their walls (mesenchymal stem cells). Whereas the medical potential of cord mesenchymal stem cells is still under investigation, the medical efficacy of cord blood hematopoietic stem cells is well established for use in the treatment of childhood leukemias.

Cord blood treatments for children have a continuing need for a method to determine the dose of the therapeutic stem cells. The Parents Guide newsletter feature describes the two industry standards for certifying cord blood units, flow cytometry and the colony-forming unit (CFU) test. Although they are currently industry certification requirements, neither of these methods gives the stem cell dose or tells which cord blood units will be effective. By some reports, this deficiency leaves nearly 20% of treated children at risk for death.

This Junes article is the Parents Guide newsletters second feature on Asymmetrexs tissue stem cell counting technology. The first feature appeared in the January 2019 issue of the newsletter. It related the historical context, envisioned applications, and potential impact of kinetic stem cell (KSC) counting, but did not delve into how the technology worked. The latest feature uses a graphical slide format to illustrate how Asymmetrex applies computational simulation to conventional cell count data to determine the number of tissue stem cells in a sample. Asymmetrexs President and CEO James L. Sherley, M.D., Ph.D. is confident that the newsletters presentation will help both non-experts and experts to understand how Asymmetrex counts therapeutic tissue stem cells.

In the intervening 3 years, the companys KSC counting technology has advanced greatly. Just in the previous week, at the Meeting in the Millyard Summit of the Advanced Regenerative Manufacturing Institute, the company announced rapid-counting algorithms that will make stem cell counting sufficiently efficient to be performed routinely for research and medicine. CEO Sherley says that he is looking forward to a future Parents Guide newsletter reporting the use of KSC counting to identify cord blood units that work all of the time for children, instead of only about 80% of the time as now.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The companys U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems stem cell-specific quantification and stem cell expansion that have stood in the way of more-effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets kinetic stem cell (KSC) counting, the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation medicine and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute | BioFabUSA (ARMI) and the Massachusetts Biotechnology Council (MassBio).

Share article on social media or email:

Read more:
Asymmetrex's Kinetic Stem Cell (KSC) Counting Technology Is Featured in the Parent's Guide to Cord Blood Foundation June Newsletter - PR Web

NK Cell Therapy and Stem Cell Therapy Market Share, Size Global Industry Revenue, Business Growth, Demand and Applications Market Research Report to…

Global NK Cell Therapy and Stem Cell Therapy Market segments and their analysis offer a complete In-depth view of the industry to readers including stakeholders, vendors, suppliers, investors, buyers, and others too.

Global NK Cell Therapy and Stem Cell Therapy Market research report represents a In-Depth overview of the current market situation and forecast till 2029. The study perhaps a perfect mixture of qualitative and quantitative information highlighting key market developments, challenges, competition industry analysis and new opportunities available and trend within the NK Cell Therapy and Stem Cell Therapy Market. Further, this report gives NK Cell Therapy and Stem Cell Therapy Market size, recent trends, growth, share, development status, market dynamics, cost structure, and competitive landscape. The research report also includes the present market and its growth potentials in the given period of forecast. An exhaustive and professional study of the global NK Cell Therapy and Stem Cell Therapy market report has been completed by industry professionals and presented in the most particular manner to present only the details that matter the most. The report mainly focuses on the most dynamic information of the global market.

Get a sample PDF of the report https://www.marketreportsworld.com/enquiry/request-sample/21038622

About NK Cell Therapy and Stem Cell Therapy Market:-

The NK Cell Therapy and Stem Cell Therapy market has witnessed a growth from USD million to USD million from 2017 to 2022. With a CAGR of this market is estimated to reach USD million in 2029.

The report focuses on the NK Cell Therapy and Stem Cell Therapy market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19.

Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. Moreover, customer preference analysis, market dynamics (drivers, restraints, opportunities), new product release, impact of COVID-19, regional conflicts and carbon neutrality provide crucial information for us to take a deep dive into the NK Cell Therapy and Stem Cell Therapy market.

The global NK Cell Therapy and Stem Cell Therapy market size is segmented on the basis of application, end user, and region, with focus on manufacturers in different regions. The study has detailed the analysis of different factors that increase the industries growth. This study also provides the scope of different segments and applications that can potentially influence the industry in the future. Pricing analysis is covered in this report according to each type, manufacturer, regional analysis, price. NK Cell Therapy and Stem Cell Therapy Market Share report provides overview of market value structure, cost drivers, various driving factors and analyze industry atmosphere, then studies global outline of industry size, demand, application, revenue, product, region and segments. In addition, this report introduces market competition situation among the distributers and manufacturers profile, besides, market value analysis and cost chain structure are covered in this report.

Get a Sample Copy of the NK Cell Therapy and Stem Cell Therapy Market Report 2022

TOP Manufactures in NK Cell Therapy and Stem Cell Therapy Market are:

NK Cell Therapy and Stem Cell Therapy Market Forecast by regions, type and application, with sales and revenue, from 2021 to 2029. NK Cell Therapy and Stem Cell Therapy Market Share, distributors, major suppliers, changing price patterns and the supply chain of raw materials is highlighted in the report.NK Cell Therapy and Stem Cell Therapy Market Size report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.This Report Focuses on the NK Cell Therapy and Stem Cell Therapy Market manufacturers, to study the sales, value, market share and development plans in the future. It is Define, describe and forecast the NK Cell Therapy and Stem Cell Therapy Market Growth by type, application, and region to Study the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. Know significant trends and factors driving or inhibiting the NK Cell Therapy and Stem Cell Therapy Market growth opportunities in the market for stakeholders by identifying the high growth segments. Strategically it examines each submarket with respect to individual growth trend and their contribution to the NK Cell Therapy and Stem Cell Therapy Market.

Enquire before purchasing this report https://www.marketreportsworld.com/enquiry/pre-order-enquiry/21038622

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including

The Global NK Cell Therapy and Stem Cell Therapy Market Trends,development and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.The global NK Cell Therapy and Stem Cell Therapy Market Growth is anticipated to rise at a considerable rate during the forecast period, between 2021 and 2029. In 2021, the market was growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

To Understand How COVID-19 Impact is Covered in This Report. Request Sample copy of the report at : https://www.marketreportsworld.com/enquiry/request-covid19/21038622

NK Cell Therapy and Stem Cell Therapy Market Trend for Development and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered. NK Cell Therapy and Stem Cell Therapy Market Report also mentions market share accrued by each product in the NK Cell Therapy and Stem Cell Therapy market, along with the production growth.

Regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:

North America (Covered in Chapter 6 and 13)

Europe (Covered in Chapter 7 and 13)

Asia-Pacific (Covered in Chapter 8 and 13)

Middle East and Africa (Covered in Chapter 9 and 13)

South America (Covered in Chapter 10 and 13)

Chapters Included in NK Cell Therapy and Stem Cell Therapy Market Report:

Purchase this report (Price 3450 USD for a single-user license) https://www.marketreportsworld.com/purchase/21038622

Some of the Key Questions Answered in this Report:

Detailed TOC of Global NK Cell Therapy and Stem Cell Therapy Market Development Strategy Pre and Post COVID-19, by Corporate Strategy Analysis, Landscape, Type, Application, and Leading 20 Countries

1 Market Overview 1.1 Product Definition and Market Characteristics 1.2 Global NK Cell Therapy and Stem Cell Therapy Market Size 1.3 Market Segmentation 1.4 Global Macroeconomic Analysis 1.5 SWOT Analysis

2. Market Dynamics 2.1 Market Drivers 2.2 Market Constraints and Challenges 2.3 Emerging Market Trends 2.4 Impact of COVID-19 2.4.1 Short-term Impact 2.4.2 Long-term Impact

3 Associated Industry Assessment 3.1 Supply Chain Analysis 3.2 Industry Active Participants 3.2.1 Suppliers of Raw Materials 3.2.2 Key Distributors/Retailers 3.3 Alternative Analysis 3.4 The Impact of Covid-19 From the Perspective of Industry Chain

4 Market Competitive Landscape 4.1 Industry Leading Players 4.2 Industry News 4.2.1 Key Product Launch News 4.2.2 MandA and Expansion Plans

5 Analysis of Leading Companies

6 Market Analysis and Forecast, By Product Types 6.1 Global NK Cell Therapy and Stem Cell Therapy Sales, Revenue and Market Share by Types(2017-2022) 6.1.1 Global NK Cell Therapy and Stem Cell Therapy Sales and Market Share by Types(2017-2022) 6.1.2 Global NK Cell Therapy and Stem Cell Therapy Revenue and Market Share by Types (2017-2022) 6.1.3 Global NK Cell Therapy and Stem Cell Therapy Price by Types (2017-2022) 6.2 Global NK Cell Therapy and Stem Cell Therapy Market Forecast by Types (2017-2022) 6.2.1 Global NK Cell Therapy and Stem Cell Therapy Market Forecast Sales and Market Share by Types(2022-2029) 6.2.2 Global NK Cell Therapy and Stem Cell Therapy Market Forecast Revenue and Market Share by Types(2022-2029) 6.3 Global NK Cell Therapy and Stem Cell Therapy Sales, Price and Growth Rate by Types(2017-2022)

7 Market Analysis and Forecast, By Applications 7.1 Global NK Cell Therapy and Stem Cell Therapy Sales, Revenue and Market Share by Applications(2017-2022) 7.1.1 Global NK Cell Therapy and Stem Cell Therapy Sales and Market Share by Applications(2017-2022) 7.1.2 Global NK Cell Therapy and Stem Cell Therapy Revenue and Market Share by Applications(2017-2022)

8 Market Analysis and Forecast, By Regions 8.1 Global NK Cell Therapy and Stem Cell Therapy Sales by Regions(2017-2022) 8.2 Global NK Cell Therapy and Stem Cell Therapy Market Revenue by Regions(2017-2022) 8.3 Global NK Cell Therapy and Stem Cell Therapy Market Forecast by Regions(2022-2029)

9 North America NK Cell Therapy and Stem Cell Therapy Market Analysis 9.1 Market Overview and Prospect Analysis 9.2 North America NK Cell Therapy and Stem Cell Therapy Market Sales and Growth Rate(2017-2022) 9.3 North America NK Cell Therapy and Stem Cell Therapy Market Revenue and Growth Rate(2017-2022) 9.4 North America NK Cell Therapy and Stem Cell Therapy Market Forecast 9.5 The Influence of COVID-19 on North America Market 9.6 North America NK Cell Therapy and Stem Cell Therapy Market Analysis by Country

10 Europe NK Cell Therapy and Stem Cell Therapy Market Analysis 10.1 Market Overview and Prospect Analysis 10.2 Europe NK Cell Therapy and Stem Cell Therapy Market Sales and Growth Rate(2017-2022) 10.3 Europe NK Cell Therapy and Stem Cell Therapy Market Revenue and Growth Rate(2017-2022) 10.4 Europe NK Cell Therapy and Stem Cell Therapy Market Forecast 10.5 The Influence of COVID-19 on Europe Market 10.6 Europe NK Cell Therapy and Stem Cell Therapy Market Analysis by Country

11 Asia-Pacific NK Cell Therapy and Stem Cell Therapy Market Analysis 11.1 Market Overview and Prospect Analysis 11.2 Asia-Pacific NK Cell Therapy and Stem Cell Therapy Market Sales and Growth Rate(2017-2022) 11.3 Asia-Pacific NK Cell Therapy and Stem Cell Therapy Market Revenue and Growth Rate(2017-2022) 11.4 Asia-Pacific NK Cell Therapy and Stem Cell Therapy Market Forecast 11.5 The Influence of COVID-19 on Asia Pacific Market 11.6 Asia-Pacific NK Cell Therapy and Stem Cell Therapy Market Analysis by Country

12 South America NK Cell Therapy and Stem Cell Therapy Market Analysis 12.1 Market Overview and Prospect Analysis 12.2 South America NK Cell Therapy and Stem Cell Therapy Market Sales and Growth Rate(2017-2022) 12.3 South America NK Cell Therapy and Stem Cell Therapy Market Revenue and Growth Rate(2017-2022) 12.4 South America NK Cell Therapy and Stem Cell Therapy Market Forecast 12.5 The Influence of COVID-19 on South America Market 12.6 South America NK Cell Therapy and Stem Cell Therapy Market Analysis by Country

13 Middle East and Africa NK Cell Therapy and Stem Cell Therapy Market Analysis 13.1 Market Overview and Prospect Analysis 13.2 Middle East and Africa NK Cell Therapy and Stem Cell Therapy Market Sales and Growth Rate(2017-2022) 13.3 Middle East and Africa NK Cell Therapy and Stem Cell Therapy Market Revenue and Growth Rate(2017-2022) 13.4 Middle East and Africa NK Cell Therapy and Stem Cell Therapy Market Forecast 13.5 The Influence of COVID-19 on Middle East and Africa Market 13.6 Middle East and Africa NK Cell Therapy and Stem Cell Therapy Market Analysis by Country

14 Conclusions and Recommendations 14.1 Key Market Findings and Prospects 14.2 Advice for Investors

15 Appendix 15.1 Methodology 15.2 Research Data Source

Continued

Browse complete table of contents at https://www.marketreportsworld.com/TOC/21038622

About Us:

Market Reports Worldis the Credible Source for Gaining the Market Reports that will Provide you with the Lead Your Business Needs. Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.

Contact Us:

Market Reports World

Phone:US : +(1) 424 253 0946 UK : +(44) 203 239 8187

Email:[emailprotected] Web:https://www.marketreportsworld.com

Other Reports Here:

Amino Silicone Oil Market Share, Size, Growth Industry Trends, Global Competitors Strategy, Segments, Regional Analysis, Review, Key Players Profile, Statistics and Growth to 2028 Analysis

Foundry Binder Market Size, Growth 2022 Global Industry Updates, Leading Players, Future Business Prospects, Forthcoming Developments and Future Investments by Forecast to 2028

Cooling Fan Market Share, Size Global Industry Revenue, Business Growth, Demand and Applications Market Research Report to 2028

Pharmaceutical Grade Phycocyanin Market Share 2022 Global Future Regional Trend, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2028

LED Retrofit Market Share, Size 2022 : Global Key Findings, Industry Demand, Growth Status, Regional Analysis, Key Players Profiles, Future Prospects and Forecast to 2028

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit NK Cell Therapy and Stem Cell Therapy Market Share, Size Global Industry Revenue, Business Growth, Demand and Applications Market Research Report to 2029

Read more here:
NK Cell Therapy and Stem Cell Therapy Market Share, Size Global Industry Revenue, Business Growth, Demand and Applications Market Research Report to...

World Sickle Cell Day 2022: Know all about symptoms and treatment of the disease – Firstpost

Symptoms of the disease are usually visible at the age of 5 months and change over time. Some of the common symptoms include pain, anaemia, frequent infections, swelling of hands and feet and vision problem

Sickle-shaped cells and normal blood cells in human blood. Image courtesy: Wikimedia Commons/Dr Graham Beards

World Sickle Cell Day is marked every year on 19 June with an aim to raise awareness about sickle cell disease. Sickle Cell Disease is a group of disorders that impact haemoglobin, the molecule in red blood cells which deliver oxygen to cells throughout the body.

Individuals who live with this disease have haemoglobin S, an atypical haemoglobin molecule which distorts red blood cells into a sickle or a crescent shape. The disease is usually transmitted from parents to children.

What are the symptoms?

Symptoms of the disease are usually visible at the age of 5 months and change over time. Some of the common symptoms include pain, anaemia, frequent infections, swelling of hands and feet and vision problem.

What are the different types of Sickle Cell Disease?

If one of the parents has a problem gene, then the child will not have symptoms but will possess sickle cell trait.

What is the treatment?

The disease can be detected in an infant during the screening process of a newborn. In case, there is a family history of the Sickle Cell disease, it can even be diagnosed at the time of pregnancy.

The only way to cure it is either stem cell or a bone marrow transplant. The symptoms can also be dealt with the use of antibiotics, periodic blood transfusion, pain killers, and vaccinations.

Read all the Latest News, Trending News,Cricket News, Bollywood News, India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.

Visit link:
World Sickle Cell Day 2022: Know all about symptoms and treatment of the disease - Firstpost

Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -…

MarketQuest.biz has announced the addition of new research titled Global Rheumatoid Arthritis Stem Cell Therapy Market from 2022 to 2028, which encompasses regional and global market data and is predicted to generate attractive valuation.The Rheumatoid Arthritis Stem Cell Therapy research covers market drivers, opportunities, limiting factors, and barriers. It provides a quantitative market study based on annual reports, product literature, industry announcements, and other sources.

The report explains the market definition, classifications, applications, engagements, and global Rheumatoid Arthritis Stem Cell Therapy industry trends are.It gives a realistic picture of the current market position incorporating original and predicted market estimates.The report gives a thorough analysis of their product portfolios to investigate the products and applications they focus on while working in the worldwide Rheumatoid Arthritis Stem Cell Therapy market. The report offers valuable suggestions to new just as set up players of the market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/121261

In order to improve industrial planning, data points such as flow patterns, openings, drivers, limits, and statistics are acquired from trusted sources. The data and numbers in the research report have been provided comprehensively, using graphical and pictorial representations to understand the market better.Further when datais synthesised, statistical analysis takes place. Several processes, including screening, integration, and data extrapolation, must be performed prior to data validation.

The product types covered in the report include:

The application types covered in the report include:

The countries covered in the market report are:

The key and emerging market players in the global market include:

ACCESS FULL REPORT: https://www.marketquest.biz/report/121261/global-rheumatoid-arthritis-stem-cell-therapy-market-2022-by-company-regions-type-and-application-forecast-to-2028

Significance of The Report gives the idea about thebroad and precise understanding, industry drivers and challenges affecting the industry growth, planning the business strategies and factors leading to the market development, and evaluating the market competition and planning

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on 1-201-465-4211 to share your research requirements.

Contact Us Mark Stone Head of Business Development Phone: 1-201-465-4211 Email: sales@marketquest.biz

Follow this link:
Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -...

Alopecia: Are there any new treatments on the horizon? – Pharmaceutical Technology

Last Friday, the US FDA decided to keep the popular anti-baldness drug finasteride on the market, but is now requiring its makers to add suicidal ideation to a list of potential side effects.

Relatedly, on 13 June, the FDA also approved Eli Lillys and Incytes Olumiant (baricitinib), the first treatment for alopecia areata, another form of baldness, which also has a positive Committee for Medicinal Products for Human Use (CHMP) recommendation for an EMA approval. Alopecia areata is an autoimmune disorder when the bodys immune cells attack the hair follicles, while androgenic alopecia is a genetically determined pattern of hair loss.

These recent regulatory actions have brought attention to the hair loss space which has ample demand for treatments, but relatively few unique assets in development.

Though we are seeing new developments in the treatment of androgenetic alopecia (AGA) emerge in recent years, such as low dose oral minoxidil and bicalutamide, effective management remains challenging, writes Dr Dmitri Wall, consultant dermatologist at Hair Restoration Blackrock in Dublin, via email.

Marketed by Organon, a Merck spinoff, finasteride sold as Propecia had global sales of $292 million in 2005, as per GlobalData. The first generic was introduced in 2006. The FDAs most recent action came in response to a petition launched by a non-profit group called the Post-Finasteride Syndrome Foundation.

In 1988, the FDA approved minoxidil, a 2% topical solution then marketed by the company Upjohn under names such as Rogaine, for male use, before receiving approval for women in 1992. Several years later, a stronger 5% formula was approved for men in 1997, with a female version receiving the green light in 2014. Upjohn merged with the Swedish company Pharmacia AB in 1995, before being acquired by Pfizer in 2002.

Almost a decade after the initial approval of minoxidil, the FDA authorized the use of 1mg finasteride tablets in 1997, a dihydrotestosterone (DHT) blocker.

Finasteride is currently not approved for use by women and is contraindicated for pregnancy, as based on Propecias FDA label. However, there are cases of advised off-label use amongst postmenopausal and occasionally premenopausal women, says Eva Proudman, consultant trichologist and chair of the Institute of Trichologists.

Finasteride and minoxidil are used with roughly 80% of patients in Proudmans estimates, seeing a very positive result. While side effects do exist, she says her practice always discusses any safety concerns.

This isnt the first time finasterides potential side effects have received attention. In 2012, the FDA requested an update of the drugs label to include mention of risks of potential sexual dysfunction. According to Mercks label for Propecia, decreased libido and erectile dysfunction were reported in 1.8% and 1.3% of 945 treated subjects respectively. The latest suicidal ideation warning comes after internal records from Merck showed the company was aware of over 200 cases of depression since 2009, as described in a Reuters exclusive last February.

At the same time, it is important to note that hair loss can prove as a very emotional process for some and there are more factors surrounding potential depression or suicidal ideation than just in case of finasteride use, says Proudman. As such, understanding what these treatments can potentially do is needed, she adds.

Moreover, some studies show that the topical treatment minoxidil is also potentially not for everyone. In a Pfizer-sponsored one-year observational study of minoxidils 5% solution from 2004, the treatment shrunk the targeted hair-loss area in 62% of subjects, but it remained unchanged in 35.1%. In the same study, 15.9% of the subjects rated the treatment as very effective, but 20.6% found it only moderately effective and 15.7% found no effects. The topical solution is intended for use in the crown and is not aimed for the treatment of frontal baldness or a receding hairline, as based on Rogaines label.

Dutasteride, another DHT blocker sold by GSK under the name Avodart, has also displayed efficacy in reducing hair loss. But the treatment has not yet been approved by the FDA for the treatment of androgenic alopecia, despite off label use.

Outside of these two established treatments, cosmetic procedures such as scalp micropigmentation, scalp reduction or hair transplantation are becoming increasingly prominent. We continue to await the delivery of safe and effective stem-cell therapy that has promised much, while limited evidence regarding adjuvant therapies such as platelet rich plasma (PRP) and low-level laser therapy (LLLT) is yet to convincingly prove their benefit, says Wall, who is also an assistant professor at the Charles Institute of Dermatology at University College Dublin.

According to GlobalDatas Pharma Intelligence Centre, there are currently 20 assets in development for androgenic alopecia. This ranges from minoxidil that is in pre-registration in Taiwan, to IVL3001, a month-lasting injection of finasteride made by the South Korean company Inventage Lab, and treatments previously unused within the space such as Cosmo Pharmaceuticals topical solution Breezula (clascosterone).

Other approaches include antiandrogens such as GT-20029 or KX-826 (pyrilutamide), developed by the Chinese pharma company Kintor Pharmaceuticals. Pyrilutamide is currently in two Phase II studies, with one for male androgenic alopecia subjects in the US, and the other for female subjects in China.

At the same time, Proudman stresses the need for efficacious products, rather than those with promises. In June 2021, the Swedish company Follicum announced its discontinuing a Phase IIa hair loss treatment FOL-005 after an independent review led to revised data showing no significant improvement.

In this sense, Proudman says it is likely that upcoming treatments will be similar to those in the available armamentarium.

"Even with the emergence of novel therapies, it remains most likely that optimal, sustained responses will require combination therapy that should be chosen after consideration of individual factors," notes Wall.

Quality Assurance and Research Tools for Pharmaceutical Developers

Global Contract Services for Pre-Clinical Studies

Contract Pharmaceutical Development Services and Commercial Manufacturing in Advanced Softgel Technologies

More:
Alopecia: Are there any new treatments on the horizon? - Pharmaceutical Technology

Cell Therapy Packaging Products and Services Market worth $1.25 Billion by 2030 – Exclusive Report by Ins – Benzinga

JERSEY CITY, N.J., June 15, 2022 /PRNewswire/ --InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Cell Therapy Packaging Products and Services Market (Therapy (T-cell Therapies, Dendritic Cell Vaccines, Stem Cell Therapies, NK Cell Therapies, and Other ATMPs), Package Engineering Design (Primary Packaging and Secondary Packaging), Scale of Operation (Clinical and Commercial)) By Trends, Industry Competition Analysis, Revenue and Forecast Till 2030"

According to the latest research by InsightAce Analytic, the global cell therapy packaging products and services market is expected to reach US$ 1,252.14 Million in 2030, recording a promising CAGR of 20.32% during the period of 2022-2030.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1265

Cell therapy aims to modify genetic material to treat different chronic diseases. Cell and gene therapy is the most significant medical advance in recent history. The increasing investments by key players in the development of promising therapies and advanced packaging technologies are anticipated to fuel the market growth over the forecast period.

Biopharmaceutical companies are investing in developing and manufacturing new customizable "patient-centered medicine" and modernizing their supply chains. Although biopharmaceutical firms' primary focus is on the drug product (DP) research and production and delivery methods (e.g., syringes), packaging and labelling are crucial to ensuring product quality and efficacy. The packaging of cell and gene therapy products must maintain closure integrity and product stability and allow simple access to the product while remaining functional during heat and mechanical loads experienced. The packaging must be designed to endure cryogenic temperatures without compromising the quality of the biological material or its longevity. For instance, In February 2022, Sharp, a leading provider in contract packaging and clinical supply services, has designed new purpose-built production suites to fulfil the rising demand from producers of gene treatments for dedicated and specialized packaging capacity. The innovative secondary packaging by Sharp aims to give an appropriate environment for tackling the challenges of gene treatments, notably at low temperatures and distribution in cold and ultra-cold supply chains. In summary, packaging technology and engineering, graphics, and labelling design are vital components of the development and marketing of gene and cell therapy programs.

Major driving factors of the cell therapy packaging products and services market are the increasing need for cell therapies, advancements in packaging and labelling, high prevalence of cancer diseases. Furthermore, advanced medical technologies, the rising trend of outsourcing in the healthcare industry, and the ongoing efforts of service providers to further improve their portfolios are enhancing the growth of the cell therapy packaging products and services market. However, the high cost of manufacturing systems, lack of standard therapy protocols, and complex procedures are restraining the growth of this market.

Geographically, the North America region is the primary revenue holder of this market due to rising awareness about cell and gene therapies, increasing government investments in the research and development of cell therapies, stringent regulations and an increasing number of human chronic diseases. On the other hand, Europe will also dominate the market during the forecast period due to advancements in the biopharmaceutical field and stringent regulations. The Asia-Pacific market is expected to grow faster in the future due to the growing cell therapy manufacturing industries and the adoption of new technologies.

Major key players in the cell therapy packaging products and services market areAlmac, Catalent Pharma Solutions, Cryoport Systems, Core Cryolab Inc., Yourway, Lufthansa Cargo, Saint-Gobain Life Sciences, Thermo Fisher Scientific, Sharp, West Pharmaceutical Services, Chart Industries Inc., and Other Prominent Players. Leading manufacturers in this field focus on novel therapy innovations, partnerships, collaborations, mergers, and agreements. These strategies will help to boost their growth opportunities in this market.

Key Developments:

Curious about this latest version of report? Enquire Before Buying @https://www.insightaceanalytic.com/enquiry-before-buying/1265

Market Segments

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Therapy

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Package Engineering Design

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Scale of Operation

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Region

North America cell therapy packaging products and services market revenue (US$ Million) by Country, 2022 to 2030

Europe cell therapy packaging products and services market revenue (US$ Million) by Country, 2022 to 2030

Asia Pacific cell therapy packaging products and services market revenue (US$ Million) by Country,2022 to 2030

Latin Americacell therapy packaging products and services market revenue (US$ Million) by Country, 2022 to 2030

Middle East & Africa cell therapy packaging products and services market revenue (US$ Million) by Country, 2022 to 2030

For Customized Information @ https://www.insightaceanalytic.com/customisation/1265

Other Related Reports Published by InsightAce Analytic:

Global Cell and Gene Therapy Bioassay Services Market

Global Vaccine Cold Chain Logistics Market

Global Cell and Gene Therapy Drug Delivery Devices Market

Why should buy this report:

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact US:

InsightAce Analytic Pvt. Ltd. Tel.: +1 718 593 4405 Email:info@insightaceanalytic.com Site Visit:www.insightaceanalytic.com Follow Us on LinkedIn @bit.ly/2tBXsgS Follow Us OnFacebook@bit.ly/2H9jnDZ

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

SOURCE InsightAce Analytic Pvt. Ltd.

See the article here:
Cell Therapy Packaging Products and Services Market worth $1.25 Billion by 2030 - Exclusive Report by Ins - Benzinga

Scientists harness light therapy to target and kill cancer cells in world first – The Guardian

Scientists have successfully developed a revolutionary cancer treatment that lights up and wipes out microscopic cancer cells, in a breakthrough that could enable surgeons to more effectively target and destroy the disease in patients.

A European team of engineers, physicists, neurosurgeons, biologists and immunologists from the UK, Poland and Sweden joined forces to design the new form of photoimmunotherapy.

Experts believe it is destined to become the worlds fifth major cancer treatment after surgery, chemotherapy, radiotherapy and immunotherapy.

The light-activated therapy forces cancer cells to glow in the dark, helping surgeons remove more of the tumours compared with existing techniques and then kills off remaining cells within minutes once the surgery is complete. In a world-first trial in mice with glioblastoma, one of the most common and aggressive types of brain cancer, scans revealed the novel treatment lit up even the tiniest cancer cells to help surgeons remove them and then wiped out those left over.

Trials of the new form of photoimmunotherapy, led by the Institute of Cancer Research, London, also showed the treatment triggered an immune response that could prime the immune system to target cancer cells in future, suggesting it could prevent glioblastoma coming back after surgery. Researchers are now also studying the new treatment for the childhood cancer neuroblastoma.

Brain cancers like glioblastoma can be hard to treat and, sadly, there are too few treatment options for patients, the study leader, Dr Gabriela Kramer-Marek, told the Guardian. Surgery is challenging due to the location of the tumours, and so new ways to see tumour cells to be removed during surgery, and to treat residual cancer cells that remain afterwards, could be of great benefit.

The ICRs team leader in preclinical molecular imaging added: Our study shows that a novel photoimmunotherapy treatment using a combination of a fluorescent marker, affibody protein and near-infrared light can both identify and treat leftover glioblastoma cells in mice. In the future, we hope this approach can be used to treat human glioblastoma and potentially other cancers, too.

The therapy combines a special fluorescent dye with a cancer-targeting compound. In the trial in mice, the combination was shown to dramatically improve the visibility of cancer cells during surgery and, when later activated by near-infrared light, to trigger an anti-tumour effect.

Scientists from the ICR, Imperial College London, the Medical University of Silesia, Poland, and the Swedish company AffibodyAB believe the novel treatment could help surgeons more easily and effectively remove particularly challenging tumours, such as those in the head and neck.

The joint effort was largely funded by the Cancer Research UK Convergence Science Centre at the ICR and Imperial College London a partnership that brings together international scientists from engineering, physical and life sciences specialisms to find innovative ways to tackle cancer.

Multidisciplinary working is critical to finding innovative solutions to address the challenges we face in cancer research, diagnosis and treatment and this study is a great example, said Prof Axel Behrens, the leader of the cancer stem cell team at the ICR and scientific director of the Cancer Research UK Convergence Science Centre.

This research demonstrates a novel approach to identifying and treating glioblastoma cells in the brain using light to turn an immunosuppressive environment into an immune-vulnerable one, and which has exciting potential as a therapy against this aggressive type of brain tumour.

Sign up to First Edition, our free daily newsletter every weekday morning at 7am BST

After decades of progress in treating cancer, the four main forms in existence today surgery, chemotherapy, radiotherapy and immunotherapy mean more people who are diagnosed with the disease can be treated effectively, and large numbers can live healthily for many years.

However, the close proximity of some tumours to vital organs in the body means it is vital new ways to treat cancer are developed so doctors can overcome the risk of harming healthy parts of the body. Experts believe that photoimmunotherapy could be the answer.

When tumours grow in sensitive areas of the brain such as the motor cortex, which is involved in the planning and control of voluntary movements, glioblastoma surgery can leave behind tumour cells that can be very hard to treat and which mean the disease can come back more aggressively later.

The new treatment uses synthetic molecules called affibodies. These are tiny proteins engineered in the lab to bind with a specific target with high precision, in this case a protein called EGFR which is mutated in many cases of glioblastoma.

The affibodies were then combined with a fluorescent molecule called IR700, and administered to the mice before surgery. Shining light on the compounds caused the dye to glow, highlighting microscopic regions of tumours in the brain for surgeons to remove. The laser then switched to near-infrared light, which triggered anti-tumour activity, killing the remaining cells after surgery.

Photoimmunotherapies could help us to target the cancer cells that cant be removed during surgery, which may help people live longer after their treatment, said Dr Charles Evans, the research information manager at Cancer Research UK. He cautioned that there were still technical challenges to overcome, such as reaching all parts of a tumour with near-infrared light, but added that he was excited to see how this research will develop.

Read the original:
Scientists harness light therapy to target and kill cancer cells in world first - The Guardian

Sernova to Participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June – StreetInsider.com

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

LONDON, Ontario, June 15, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that Dr. Philip Toleikis, President & CEO of Sernova Corp, will be participating in the Truist Securities Cell Therapy Symposium, Symposia-cel being held in person at the Lotte New York Palace on Tuesday, June 28, 2022. Company management will also be participating in 1x1 meetings during the event.

* Further details available on the Truist event website

If you are interested in arranging a 1x1 meeting request, please contact your Truist representative.

ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY

Sernova Corp is a clinical-stage biotechnology company that is developing regenerative medicine therapeutic technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders like hemophilia A. Sernova is currently focused on finding a functional cure for insulin-dependent diabetes with its lead asset, the Cell-Pouch SystemTM, a novel implantable and scalable medical device which forms a natural environment in the body for long-term survival and function of therapeutic cells that release necessary proteins or factors missing from the body to treat chronic diseases. Sernovas Cell Pouch System has already shown it can potentially provide a functional cure to people with type 1 diabetes in an ongoing Phase I/II study at the University of Chicago. Sernova is also working on technology with the University of Miami to cloak the implant from the immune system, to eliminate the need for immunosuppressives to protect the cells from immune system attack. In May 2022, Sernova and Evotec entered into a global strategic partnership to develop an implantable off-the-shelf iPSC-based (induced pluripotent stem cells) beta cell replacement therapy. This partnership provides Sernova an unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova is also gearing up to be in the clinic in two additional programs that utilize its Cell Pouch System an implantable cell therapy for benign thyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral factor 8 gene therapy for hemophilia A.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Corporate: Christopher Barnes VP, Investor Relations Sernova Corp. [emailprotected] 519-902-7923 http://www.sernova.com

Investors: Corey Davis, Ph.D. LifeSci Advisors, LLC [emailprotected] 212-915-2577

Media: Elizabeth Miller, M.D. LifeSci Communications [emailprotected]

Read more:
Sernova to Participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June - StreetInsider.com

Novartis five-year Kymriah data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL -…

Basel, June 12, 2022 Novartis today announced long-term results from the ELIANA pivotal clinical trial of Kymriah (tisagenlecleucel), the first-ever approved CAR-T cell therapy, in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL), with a maximum survival follow-up of 5.9 years. For the 79 patients treated with Kymriah in this study, the five-year overall survival (OS) rate was 55% (95% CI, 43-66), while the median event-free survival (EFS) for patients in remission within three months of infusion (n=65) was 43.8 months. These findings demonstrate the curative potential of Kymriah, the only CAR-T cell therapy available for these patients who previously had limited treatment options. These data were presented as an oral presentation during the 2022 European Hematology Association (EHA) Hybrid Congress (Abstract #S112)1.

These data mark a moment of profound hope for children, young adults and their families with relapsed or refractory B-cell ALL, as relapse after five years is rare, said Stephan Grupp, MD, PhD, Section Chief of the Cellular Therapy and Transplant Section, and Inaugural Director of the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy at Children's Hospital of Philadelphia (CHOP). Since the approval of Kymriah nearly five years ago, we have been able to offer a truly game-changing option to patients who previously faced a five-year survival rate of less than 10 percent.

This long-term follow up of ELIANA demonstrated the potential for Kymriah to transform cancer treatment in pediatric and young adult patients with r/r B-cell ALL, significantly improving outcomes with durable responses and a consistent safety profile in this patient population1:

At Novartis, we strive for cures. With nearly six-year follow-up data in these pediatric and young adults treated for B-cell ALL, we have our strongest evidence yet that one-time treatment with Kymriah has curative potential, said Jeff Legos, Executive Vice President, Global Head of Oncology & Hematology Development. These results strengthen our confidence in CAR-T cell therapies as a truly transformative and paradigm-shifting advance in cancer care, as well as our commitment to continue developing this technology with next-generation platforms.

Additional updates on the Novartis CAR-T program presented at the 2022 EHA Congress include new data from more patients and longer follow-up from the first-in-human dose-escalation trials with YTB323 in adults with r/r diffuse large B-cell lymphoma and PHE885 in adults with r/r multiple myeloma, the first Novartis CAR-T cell therapies developed using the Novartis T-Charge platform2,3,4. Visit https://www.hcp.novartis.com/virtual-congress/eha-2022/ to learn more about these data and our ongoing commitment to reimagining cancer care with CAR-T cell therapies.

About Kymriah Kymriah is the first-ever FDA-approved CAR-T cell therapy. It is a one-time treatment designed to empower patients immune systems to fight their cancer. Kymriah is currently approved for the treatment of r/r pediatric and young adult (up to and including 25 years of age) acute lymphoblastic leukemia (ALL), r/r adult diffuse large B-cell lymphoma (DLBCL) and r/r adult follicular lymphoma1.

About the ELIANA Trial ELIANA was the first pediatric global CAR-T cell therapy registration trial, examining patients in 25 centers in 11 countries across the US, Canada, Australia, Japan and the EU, including: Austria, Belgium, France, Germany, Italy, Norway and Spain. The trial was an open-label, multicenter, single-arm, global Phase II trial investigating the efficacy and safety of Kymriah in pediatric and young adult patients in r/r B-cell ALL who were primary refractory, chemorefractory, relapsed after, or were not eligible for allogeneic stem cell transplantation (SCT). The primary endpoint was overall remission rate (ORR), defined as best overall response of CR or CR with incomplete blood count recovery (CRi) within 3 months and maintained for 28 day. The secondary endpoints include CR/CRi with undetectable minimal residual disease (MRD), duration of remission, event-free survival, overall survival, cellular kinetics and safety5.

About T-Charge T-Charge is a next-generation CAR-T platform, innovated at the Novartis Institutes for BioMedical Research (NIBR), that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. By implementing the T-Charge platform, we aim to revolutionize CAR-T cell therapy with new products that have the potential to offer patients a higher likelihood of better and more durable responses, improved long-term outcomes and a reduced risk of severe adverse events. The T-Charge platform preserves T cell stemness (T cell ability to self-renew and mature), an important T cell characteristic closely tied to its therapeutic potential, which results in a product containing greater proliferative potential and fewer exhausted T cells. With T-Charge, CAR-T cell expansion occurs primarily within the patients body (in-vivo), eliminating the need for an extended culture time outside of the body (ex-vivo). The T-Charge platform, which implements important process efficiencies, will be rapid, compared with traditional CAR-T, and reliable, through simplified processes and streamlined quality control. Multiple CAR-T therapies, including YTB323 and PHE885, are being developed using the Novartis T-Charge platform.

About Novartis commitment to Oncology Cell Therapy As part of the unique Novartis strategy to pursue four cancer treatment platforms radioligand therapy, targeted therapy, immunotherapy and cell and gene therapy we strive for cures through cell therapies in order to enable more patients to live cancer-free. We will continue to pioneer the science and invest in our manufacturing and supply chain process to further advance transformative innovation.

Novartis was the first pharmaceutical company to significantly invest in pioneering CAR-T research and initiate global CAR-T trials. Kymriah, the first approved CAR-T cell therapy, developed in collaboration with the Perelman School of Medicine at the University of Pennsylvania, is the foundation of the Novartis commitment to CAR-T cell therapy.

We have made strong progress in broadening our delivery of Kymriah, which is currently available for use in at least one indication in 30 countries and at more than 370 certified treatment centers, with clinical and real-world experience from administration to more than6,900 patients. We continue to pioneer in cell therapy, leveraging our vast experience to develop next-generation CAR-T cell therapies. These therapies will utilize our new T-Charge platform being evaluated to expand across hematological malignancies and bring hope for a cure to patients with other cancer types.

Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as potential, can, will, plan, may, could, would, expect, anticipate, seek, look forward, believe, committed, investigational, pipeline, launch, or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AGs current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Novartis is reimagining medicine to improve and extend peoples lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the worlds top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more athttps://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews For Novartis multimedia content, please visit https://www.novartis.com/news/media-library For questions about the site or required registration, please contact [emailprotected]

References

# # #

Novartis Media Relations E-mail: [emailprotected]

Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: [emailprotected]

Here is the original post:
Novartis five-year Kymriah data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL -...

These are the non-surgical facelift treatments to consider for glowing skin – VOGUE India

As eerily relevant as 1992s Death Becomes Her is in 2022, there is an unexpected difference. Unlike Madeline (Meryl Streep) and Helen (Goldie Hawn), we arent hiding our facelifts. Instead, some of us are live streaming the whole experience. Dermal fillers and Botox are getting as common as getting a facial in your local salon.

"There has been a shift of mindset and increased acceptability of these procedures, says Dr Madhuri Agarwal of Yavana Aesthetics, Mumbai. In the next few years, the trend is going to be more innovations and better delivery mechanisms of these minimally invasive procedures that deliver long term, healthy skin.

What you want to do to look and feel good is not up for discussion. While lasers and acids are wonderful for skin texture and even tightening, a non-surgical facelift involving needles can be more effective for the latter. For example, filler that is more natural looking, because a laser isnt doing anything to make up for the lost volume.

Our bodies are dynamic and need maintenance as we age. Even, and especially, our facial skin. But with so many options of non-surgical face lifts available, it can be overwhelming to make a choice. We spoke to a few dermatologists to help break down the details of the best non-surgical facelift treatments involving needles.

Botox involves injecting a very safe neurotoxin called Botulinum to freeze muscles, and relax them, ironing out wrinkles. Wary but curious first timers can choose to start with very minute unitsthey wont erase all wrinkles but will smoothen them out enough to look a little more natural. I suggest this only when fine lines form, says Dr Kiran Sethi, a dermatologist based in Delhi and author of Skin Sense. It lasts 3-6 months, and there isnt much downtime. Its great when combined with fillers or skin boosters. Theres also been a focus on preventive Botox. If you get it done before the lines set in, you will have fewer lines as you age, explains Dr Geetika Mittal Gupta of ISAAC Luxe Clinic in Mumbai and Delhi. You will need less and less Botox as you age, because those muscles are not contracting as much. And by early I mean, when you see certain lines of ageing.

Fillers are usually injections of hyaluronic acid that add back lost volume to parts of your face. The Indian bone structure is such that our cheekbone is a little flat on the centre part of the face, explains Dr. Chytra V Anand, founder, Kosmoderma located in Chennai and Bengaluru. So most Indians, even teenagers, get dark circles and hollows. Its a loss of volume. So you have to put a filler in there. And people are accepting of that. Its not because they want to look like someone else, or they want to look younger. They just want to maintain their body and skin. The down time for fillers is usually 2-7 days, depending on how easily you bruise. And a good treatment can last anywhere between 1 and 2 years.

The vampire facial might have shocked people a few years ago, but today its one of the most popular treatments in India. Platelet-rich plasma is extracted from your blood, rich in growth hormones that renews blood flow and tissue regeneration wherever it is injected back, including your scalp. Its usually a course of 3-4 sessions, monthly, says Dr Sethi. It treats melasma, dehydration, has a mild filler effect too. And when used on the scalp, new hair growth can show in 6 months.

Theres also stem cell therapy for hair and skin rejuvenation. We take a small biopsy of the skin, splice the cells, and use the extract for regenerative therapy, says Dr Anand. It takes less time and commitment than PRP and is great for scar healing.

Its good to remember that these treatments are addictive too, says Dr Akber Aimer, Director of Aesthetic Medicine, Maya Medi Spa. You need to understand your limit. Always look for a good doctor who is experienced and talk about your problems and ask their opinions. Understand everything clearly. Your decision-making is a multi-step procedure. You need to have done proper research on the materials used and the treatment. Understand the technology. Trust your gut. And dont forget to ask for before and after pictures!

LED light therapy can help you achieve your skincare goals

In-clinic skincare treatments: How theyve evolved with the lockdowns

Here's how to get glowing skin for the summer, according to experts

Go here to read the rest:
These are the non-surgical facelift treatments to consider for glowing skin - VOGUE India